

When gut spasm has 'em

Even if your patients persist with the diet you recommend, it may not be enough to control the pain and spasm of irritable bowel syndrome.

If that is the case, it's a good case for new Merbentyl 20.

A 28-day t.d.s. course of this new presentation of an established antispasmodic should resolve the problem.

So when diet alone just won't do, remember to get it right by writing Merbentyl 20.

PRESCRIBING INFORMATION

PRESENTATION: White, biconvex, oval tablets, stamped Merbentyl 20 containing Dicyclomine Hydrochloride BP 20 mg.

USES: Merbentyl is a smooth muscle antispasmodic primarily indicated for the treatment of functional conditions involving smooth muscle spasm of the gastro-intestinal tract.

DOSAGE & ADMINISTRATION: Adults and children over 12 years: One tablet (20 mg) three times daily before or after meals.

CONTRA-INDICATIONS, WARNINGS, ETC: Known idiosyncrasy to Dicyclomine Hydrochloride BP.

PRECAUTIONS: Products containing dicyclomine hydrochloride should be used with caution in any patient with or suspected of having glaucoma or prostatic hypertrophy. Use with care in patients with hiatus hernia associated with reflux oesophagitis because anticholinergic drugs may aggravate the condition. Since the risk of teratogenicity cannot be excluded with absolute certainty for any product, the drug should be used during pregnancy only if clearly needed.

It is not known whether dicyclomine is secreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when dicyclomine is administered to a nursing woman.

SIDE-EFFECTS: Side-effects seldom occur with Merbentyl. However, in susceptible individuals, dry mouth, thirst and dizziness may occur. On rare occasions, fatigue, sedation, blurred vision, rash, constipation, anorexia, nausea and vomiting, headache and dysuria have also been reported.

PHARMACEUTICAL PRECAUTIONS: None. **LEGAL CATEGORY:**

[POM] PACKAGE QUANTITIES: Packs of 84 tablets. **FURTHER INFORMATION:** Nil. **PRODUCT LICENCE NUMBERS:** PL 4425/0081, PA 41/5/1. **BASIC NHS PRICE:** 84 tablets £4.89 (Oct. 1986). **NAME AND ADDRESS OF LICENCE HOLDER:** Merrell Dow Pharmaceuticals Limited, Stana Place, Fairfield Avenue, Staines, Middlesex TW18 4SX. **TRADEMARKS:** Merrell, Dow, Merbentyl.

Merrell® Dow





Three times daily
and the right diet


NEW

MERBENTYL

20 mg Dicyclomine Hydrochloride BP antispasmodic

THOMAS MORSON PHARMACEUTICALS BUILDING FOR THE FUTURE





Building on strength

On the strength of our parent company, Merck Sharp & Dohme Limited, one of the largest manufacturers of prescribed medicines in the world.

Building on experience

On the foundations of the extensive history of Thomas Morson Pharmaceuticals, which spans over a century.

Building on research and commitment

On the benefits of sharing over £250 million invested annually by MSD on research, which has helped establish Thomas Morson Pharmaceuticals in a wide range of therapeutic areas, including arthritis and cardiovascular disease.

Building for the future

A future committed to improved patient care through medical advances in all therapeutic areas, notably gastroenterology, and the beneficial implications for the many thousands of sufferers of distressing digestive disorders.

Thomas Morson Pharmaceuticals—
new directions, new purposes




Thomas Morson Pharmaceuticals
Hertford Road, Hoddesdon, Hertfordshire
Division of Merck Sharp & Dohme Limited

ASACOL™

MESALAZINE* (5-aminosalicylic acid)

Direct delivery to the colon

For ulcerative colitis patients
who cannot tolerate
sulphasalazine¹



ASACOL delivers 5-aminosalicylic acid directly to the colon without sulphapyridine (the agent in sulphasalazine that can cause distressing side effects).²

A patented acrylic coating on **ASACOL** makes it site-selective. **ASACOL** remains intact until it reaches the colon, where pH rises above 7 and dissolves the coating, releasing the 5-ASA.^{2,3}

Each **ASACOL** tablet provides twice as much 5-ASA (400mg) as each tablet of sulphasalazine (200mg), which allows patients to take fewer tablets daily.

Clinical studies have shown that **ASACOL** offers efficacy comparable to that of sulphasalazine in maintaining the remission of ulcerative colitis.^{4,5}

ASACOL™

Direct Delivery to the Colon

REFERENCES:

1. Dew M.J., Harries A.D., Evans B.K. et al. Treatment of ulcerative colitis with oral 5-aminosalicylic acid in patients unable to take sulphasalazine. *Lancet*, 1983, ii, 801.
2. Dew M.J., Hughes P.J., Lee M.G. et al. An oral preparation to release drugs in the human colon. *Br. J. Clin. Pharmacol.*, 1982, 14, 405-408.
3. Dew M.J., Ryder R.E., J. Evans N. et al. Colonic release of 5-aminosalicylic acid from an oral preparation in active ulcerative colitis. *Br. J. Clin. Pharmacol.*, 1983, 16, 185-187.
4. Dew M.J., Hughes P.J., Harries A.D. et al. Maintenance of remission in ulcerative colitis with oral preparation of 5-aminosalicylic acid. *Br. Med. J.*, 1982, 285, 1012-1014.
5. Dew M.J., Harries A.D., Evans N. et al. Maintenance of remission in ulcerative colitis with 5-aminosalicylic acid in high doses by mouth. *Br. Med. J.*, 1983, 287, 23-24.

*Mesalazine is the British Approved Name for 5-aminosalicylic acid.

ABBREVIATED PRESCRIBING INFORMATION

PRESENTATION

Red tablets, containing 400mg of mesalazine (5-aminosalicylic acid) coated for release in the terminal ileum and colon.

USES

For the maintenance of remission of ulcerative colitis in patients who cannot tolerate sulphasalazine.

DOSEAGE AND ADMINISTRATION

Adults: 3 to 6 tablets daily in divided doses.

There is no dose recommendation for children.

CONTRA-INDICATIONS, WARNINGS, ETC.

Contra-indications

Contra-indications: a history of sensitivity to salicylates. Children under 2 years of age.

Precautions

Renal disorder. Mesalazine is excreted rapidly by the kidney, mainly as its metabolite, N-acetyl 5-aminosalicylic acid. In rats, large doses of mesalazine injected intravenously produced tubular and glomerular toxicity. Although no renal toxicity has been reported in patients taking Asacol, it is not recommended in patients with renal impairment and caution should be exercised in patients with a raised blood urea or proteinuria.

Asacol should not be given with lactulose or similar preparations which lower stool pH and may prevent release of mesalazine.

Adverse Reactions

Adverse reactions occur in a small proportion of patients who previously could not tolerate sulphasalazine. The side-effects are predominantly gastrointestinal (nausea, diarrhoea and abdominal pain) and headache. Asacol may be associated with the exacerbation of the symptoms of colitis in those patients who have previously had such problems with sulphasalazine.

Other side effects observed with sulphasalazine such as depression of bone marrow and of sperm count and function, have not been reported with Asacol.

LEGAL CATEGORY: POM


PL: 0424/0032

Daily treatment cost: 87 pence


U.K. Patent No. 8322387

Henlow Trading Estate
Henlow, Beds. SG16 6DS

Most conventional ulcer patients can be



treated with H₂ antagonists, but...



**Now more ulcer patients may be
successfully treated with¹**

Antepsin[®]
sucralfate

Cytoprotection in action

- In patients over 55 where hypersecretion is seldom a factor²
- Those whose gastric disturbance is due to external irritants^{3,4}
- Those for whom H₂ antagonists are inadequate¹

Abbreviated Prescribing Information

Refer to data sheet for full prescribing information

Presentation: Antepsin tablets contain 1 gram sucralfate, PL0607/0045, PA149/4/2, pack size 100 tablets, £12.50. **Uses:** duodenal ulcer, gastric ulcer and chronic gastritis. **Dosage and Administration:** Adults, orally 1 gram 4 times a day to be taken one hour before meals and at bedtime. For ease of administration Antepsin tablets may be dispersed in 10-15ml of water. **Precautions:** renal dysfunction, pregnancy, nursing women (see data sheet). **Drug Interactions:** Antepsin may reduce the bioavailability of certain drugs; tetracycline,

phenytoin, cimetidine and digoxin. Administration of Antepsin with any of these drugs should be separated by two hours. Warfarin (see data sheet). **Side-effects:** constipation.

Legal Category: POM.

Date of preparation April 1985.
Antepsin is a registered trade mark.

References: 1. Guslandi, M. *et al*, GUT, 1983, 24, 498. 2. Marks, I.N., Gastrointestinal Tract Disorders in the Elderly, Edinburgh, Churchill Livingstone, 1984, 79. 3. Tesler, M.A. *et al*, J. Clin. Gastroenterol., 1981, 3, (suppl.2), 175. 4. Tarnawski, A., *et al*, Gastroenterology, 1985, 88 (No5), 1609.

**STILL AVAILABLE ON THE
NHS FOR PEPTIC ULCER
AND CHRONIC GASTRITIS**



**Ayerst[®]
International**

Ayerst Laboratories Ltd.
South Way, Andover, Hampshire SP10 5LT
Telephone: Andover (0264) 58711
Distributors in Ireland: Ayerst Laboratories Ltd.
765 South Circular Road, Islandbridge, Dublin 8


There's a lot more to

Mention the name KeyMed and every gastroenterologist will think of endoscopes.


Certainly that's how we've made our name — through supplying and servicing the extensive range of Olympus fiberscopes, the instruments of choice for those who value large bright optics, superior mechanical design, ease of handling and total accessibility for cleaning and disinfection.

Olympus instruments are still fundamental to KeyMed's business, but today there's a lot more to us than endoscopes. We've expanded our range of products on many fronts — from ultrasound to computers. So from now on, when you mention the name KeyMed, most gastroenterologists will be thinking of a lot more than just endoscopes.


For further details of our wide range of services to gastroenterology and information on specific products, please contact our Medical Customer Liaison Department.



Ultrasound Endoscopy System —
Olympus EU-M2



Haemostatic Therapy — Olympus
Heat Probe



us than endoscopes

Flexible Endoscopes — the complete Olympus OES range of diagnostic and therapeutic procedures, including electronic endoscopy.

Light Sources — a comprehensive line-up manufactured by both Olympus and KeyMed.

CCTV & Photography — from a simple 35mm camera to a complete CCTV system.

Flexible Accessories — an ever-growing range specially designed to satisfy the demands of new procedures.

Cleaning & Storage Equipment — manual and automatic cleaning systems; trolleys, cupboards and hangers for storage.

Room Service — a complete design and planning service for endoscopy units.


Patient Handling — mobile couches for the efficient movement and transfer of patients.

Medical Computer Systems — the unique Metabase software system, meeting the many administrative needs of the gastroenterology department.

Ultrasound Endoscopy System — the result of pioneering work by Olympus in the field of endoscopic ultrasonography.


Diathermy, Suction, Oesophageal Therapy, Haemostatic Therapy — advanced equipment specifically designed for endoscopic use.

**Cleaning — KeyMed
Auto-Disinfector**



**Oesophageal Therapy — KeyMed
Advanced Dilators**

**Patient Handling — KeyMed
Variable Height Couch**



The comprehensive gastroenterology service

KeyMed

Specialised Services to Medicine

KeyMed (Medical & Industrial Equipment) Ltd.

KeyMed House, Stock Road, Southend-on-Sea, Essex SS2 5QH.

Telex: 995283, Facsimile: (0702) 65677, Telephone: (0702) 616333 (24 lines).

Scotland: KeyMed, Peel House, Ladywell East, Livingston EH54 6AH. Telephone: (0506) 416655

Ireland: KeyMed Ireland Ltd., KeyMed House, Lord Edward Court, Bride Street, Dublin 8. Telephone: 774855

USA: KeyMed Inc., 400 Airport Executive Park, Spring Valley, New York 10977. Telephone: (914) 425-3100



OLYMPUS ENDOSCOPY SYSTEM

Created by Nature. Proven by Science.

For relief of irritable bowel and abdominal pain



The unique enteric-coated Colpermin capsule is a long-acting, slow-release product containing a thixotropic paste of peppermint oil. The enteric coating permits this naturally occurring medication to be delivered direct to the distal small bowel. Recent studies confirm that Colpermin offers direct relief to the patient by effectively relaxing intestinal smooth muscle to relieve colonic pain and gaseous distension.

- Irritable bowel symptoms are highly responsive to placebo, but in a recent double-blind cross-over trial, Colpermin was found to be superior to placebo in alleviating irritable bowel symptoms over a three-week period.¹

- A delayed-release preparation, Colpermin reaches the colon in an unmetabolised state, allowing it to effectively reduce colonic motility.²


- Recent ultrasound studies show a consistent inhibitory effect of topical peppermint oil on colon motility and symptomatic improvement of irritable bowel patients given peppermint oil.³

References:

1. Rees WDW, Evans BK, Rhodes J: Treating irritable bowel syndrome with peppermint oil. *Br Med J* 2:835-836, 1979.
2. Somerville KW, Richmond CR, Bell GD: Delayed release peppermint oil capsules (Colpermin) for the spastic colon syndrome: A pharmacokinetic study. Proceedings of the British Pharmacological Society, Cambridge, April 1983. *Br J Clin Pharmacol*, to be published.
3. Taylor BA, Duthie HL, Oliveira RB, et al: Ultrasound used to measure the response of colonic motility to essential oils. Proceedings of *The International Motility Symposium* Aix-en-Provence, France, September 1983, to be published.

COLPERMINTM

(enteric-coated peppermint oil) CAPSULES



PRESCRIBING INFORMATION

Presentation: Enteric-coated gelatin capsule. Each contains 0.2 ml standardised peppermint oil B.P., Ph. Eur. **Uses:** For the treatment of symptoms of discomfort and of abdominal colic and distension experienced by patients with irritable bowel syndrome. **Dosage and Administration:** One capsule three times a day, preferably before meals and taken with a small quantity of water. The capsules should *not* be taken immediately after food. The dose may be increased to two capsules, three times a day when discomfort is more severe. The capsules should be taken until symptoms resolve, usually within one or two weeks. At times when symptoms are more persistent, the capsules can be continued for longer periods of between 2 to 3 months. There is no experience in the use of these capsules in children under the age of 15 years.



Contraindications, Warnings, etc. Precautions: The capsule should not be broken or chewed. Patients who already suffer from heartburn, sometimes experience an exacerbation of these symptoms when taking the capsule. Treatment should be discontinued in these patients. **Adverse effects:** Heartburn, sensitivity reactions to menthol which are rare, and include erythematous skin rash, headache, bradycardia, muscle tremor and ataxia. **Product Licence:** PL 0424 0009. **Basic NHS Cost:** £10.58 per 100. UK and Foreign Patents pending. Colpermin is a trade mark of Tillotts Laboratories. Further information is available from Tillotts Laboratories, Henlow Trading Estate, Henlow, Beds. **European Patent No.** 0015334. **UK Patent No.** 2006011.

Henlow Trading Estate, Henlow, Beds. SG16 6DS

The Focus of Medical Technology.



As the medical profession searches tirelessly for the means to further the investigation and treatment of conditions which have so far eluded it, there is one company motivated towards helping achieve that end.

The company is Pilkington Medical Systems. Their expertise in electro-optical systems as manufacturers of medical lasers and

endoscopes combined with the considerable **research and development** capability has positioned them as one of the world's foremost medically innovative companies.

So, as the world looks for the next healthcare breakthrough, the medical profession can look to Pilkington Medical Systems

— the focus of medical technology.




PILKINGTON

◀ Medical Systems ▶

The Focus of Medical Technology.

Pilkington Medical Systems Ltd. Bleasdale Court, 2 South Avenue, Clydebank Business Park, Clydebank G81 2LE. Telephone: 041-952 1111 · Telex: 776471



A BETTER CHOICE TO LIVE WITH THROUGH THE DAY

A new trial⁽¹⁾ has shown that COLIFOAM is equal in efficacy to prednisolone enemas, but causes significantly less interference in your patients' daily lives. Published evidence now conclusively demonstrates the clear superiority of COLIFOAM compared to liquid enemas:


Efficacy. COLIFOAM is equal in efficacy to prednisolone enemas⁽¹⁾ and hydrocortisone enemas⁽²⁾. Retrograde spread increases with the extent of the disease⁽³⁾ and COLIFOAM can

reach well into the descending colon⁽⁴⁾.

Acceptability. COLIFOAM causes less interference with your patients' daily lives^(1,2,5). COLIFOAM is far easier for your patients to retain^(1,2,5).

Safety. Bioavailability data proves COLIFOAM has extremely low levels of systemic absorption⁽⁶⁾, lower than prednisolone enemas⁽⁷⁾.

Economy. COLIFOAM costs less per dose than standard proprietary enemas⁽⁸⁾.




In distal inflammatory bowel disease. A better choice every time.

References (1) Somerville KW et al. British Medical Journal 1985;291:866. (2) Ruddell WJ et al. Gut 1980;21:885-889. (3) Farthing MJ et al. British Medical Journal 1979;2:822-824. (4) Rhodes JM. Journal of Clinical & Hospital Pharmacy 1983;8:219-232. (5) Gaucher P and Champigneulle B. Revue Française de Gastroenterologie 1983;193:35-39. (6) Barr WH et al. Medical College of Virginia/Virginia Commonwealth University. FDA bioavailability submission document. October 1981. (7) Lee DAH et al. Gut 1980;21:215-218. (8) MIMS October 1985.

Prescribing Information. **Presentation** White odourless aerosol foam containing hydrocortisone acetate PhEur 10%. **Uses** Anti-inflammatory corticosteroid therapy for the topical treatment of ulcerative colitis, proctosigmoiditis and granular proctitis. **Dosage and administration** One applicatorful inserted into the rectum once or twice daily for two or three weeks and every second day thereafter. Shake can vigorously before use. (Illustrated instructions are enclosed with every pack). Satisfactory response usually occurs within five to seven days. **Contra-indications, warnings etc.** Local contra-indications to the use of intrarectal steroids include obstruction, abscess, perforation, peritonitis, fresh intestinal anastomoses and extensive fistulae. General precautions common to all corticosteroid therapy should be observed during treatment with Colifoam. Treatment should be administered with caution in patients with severe ulcerative disease because of their predisposition to perforation of the bowel wall. Safety during pregnancy has not been fully established. **Pharmaceutical precautions** Pressurized container. Protect from sunlight and do not expose to temperatures above 50°C. Do not pierce or burn even after use. Do not refrigerate. Shake vigorously before use. Keep out of reach of children. For external use only. **Legal category** POM. **Package quantities** Aerosol canister containing 25g. (approx. 14 applications) plus a plastic applicator and illustrated leaflet. **Basic NHS cost** 25g plus applicator, £7.25. **Further Information** One applicatorful of Colifoam provides a dose of approximately 125mg of hydrocortisone acetate, similar to that used in a retention enema, for the treatment of ulcerative colitis, sigmoiditis and proctitis. **Product Licence No.** 0036/0021. Further information is available on request. **Stafford-Miller Ltd.**, Professional Relations Division, Hatfield, Herts. AL10 0NZ.

Another cleaning solution from KeyMed



Manual cleaning and disinfection of fiberoptic endoscopes is a tedious and time-consuming task set against a background of the increased risk of cross-infection. Automated processing ensures a regimented and pre-determined level of decontamination on a repeatable basis.

The New KeyMed Auto-Disinfector

RELIABLE processes all Olympus OES immersible fiberoptic endoscopes providing the benefits of total immersion and all channel irrigation*.


VERSATILE self-contained, mobile and requires no plumbing.

SIMPLE scope connections are quick and easy and all functions are operated from a convenient eye-level control panel.

The KeyMed Auto-Disinfector has two pre-set programmes and also incorporates a pause facility to allow prolonged endoscope immersion in disinfectant solution when required.


For further information or to arrange a practical evaluation of the KeyMed Auto-Disinfector in your own unit, contact Medical Customer Liaison at any of the numbers below.

*excluding raiser bridge channel on JF series, GIF-K10 and GIF-D10.



Eye-level control panel operates all functions

Quick and easy scope connections



Simple access to fluid containers

**DESIGNED FOR ALL OLYMPUS
IMMERSIBLE FIBEROSCOPES**

KeyMed

Specialised Services to Medicine

KeyMed (Medical & Industrial Equipment) Ltd.
KeyMed House, Stock Road, Southend-on-Sea, Essex SS2 5QH.
Telex: 995283, Facsimile: (0702) 65677, Telephone: (0702) 616333 (24 lines)

Scotland: KeyMed, Peel House, Ladywell East, Livingston EH54 6AH. Telephone: (0506) 416655

Ireland: KeyMed Ireland Ltd., KeyMed House, Lord Edward Court, Bride Street, Dublin 8. Telephone: 774855

USA: KeyMed Inc., 400 Airport Executive Park, Spring Valley, New York 10977. Telephone: (914) 425-3100



Medical Equipment

IN IRRITABLE BOWEL

SpasmonalTM

alverine citrate

Objective assessment in a recent hospital study demonstrated that SPASMONAL significantly reduces colonic motor activity,⁽¹⁾ providing relief from gut spasm and pain.

SPASMONAL has been proven to relieve colicky pain and help normalise bowel habit; to be at least as effective as mebeverine⁽²⁾ with the advantage of being lactose free.

Rx 1 capsule tds (100)

Presentation: Blue/grey opaque hard gelatin capsules each containing 60mg Alverine Citrate USNF XIII.

Uses: Selective smooth muscle spasmolytic.

Dosage and administration: Adults 1 or 2 capsules one to three times daily, orally. No specific dosage recommendation can be made for children.

Contra-indications, warnings, etc: Nil.

Pharmaceutical precautions: Store in a cool dry place.

Legal category: P.

Package quantities: 100 capsules.

Usual daily treatment cost: 30 pence.

Further information: Alverine citrate is a synthetic non-narcotic, non-habit-forming spasmolytic of a low order of toxicity in comparison with other antispasmodics. It has a specific effect on the smooth muscle of the intestine and uterus, but not on that of the respiratory or cardiovascular system.

Product licence number: 0322/5014.

(1) Trotman, I.F. Presented at the XII International Congress of Gastroenterology, Lisbon, 1984.

(2) Tudor, G.J., Br J Clin Pract 1986; 40: 276-278.

Spasmonal is a British Product.


Spasmonal and Norgine are trademarks.

Further information is available from:



Norgine Limited,
116-120 London Road,
Oxford, OX3 9BA.

This publication is available in microform.



University Microfilms International reproduces this publication in microform: microfiche and 16mm or 35mm film. For information about this publication or any of the more than 13,000 titles we offer, complete and mail the coupon to: University Microfilms International, 300 N. Zeeb Road, Ann Arbor, MI 48106. Call us toll-free for an immediate response: 800-521-3044. Or call collect in Michigan, Alaska and Hawaii: 313-761-4700.

☐ Please send information about these titles:

Name _____

Company/Institution _____

Address _____

City _____

State _____ Zip _____

Phone () _____

University
Microfilms
International

Report on the Bilateral Agreement for the Publishing of the Chinese Edition of *Scandinavian Journal of Gastroenterology* in Shanghai, 1 August 1986

Erratum

Review: Gastrointestinal Regulatory Peptides: Radioimmunoassay and Biological Activity

Effects of Food Intake and Various Extrinsic Hormones on Portal Blood Flow in Patients with Liver Cirrhosis Demonstrated by Pulsed Doppler with the Octoson

Lysophosphatidylcholine and Taurodeoxycholate Increase Stomach Permeability to Different-Sized Molecules

Effects of Pirenzepine and Atropine on Gastroduodenal Motor Patterns in Duodenal Ulcer Patients

Enzyme Activities in Biopsy Specimens from Human Gastric Mucosa

Screening for Coeliac Disease in Adults by Simultaneous Determination of IgA and IgG Gliadin Antibodies

Treatment of Duodenal Ulcer with Low-Dose Antacids

The Effect of Vagal Stimulation on the Release of Cholecystokinin in Anaesthetized Pigs

Lysolecithin Affects the Viscosity, Permeability, and Peptic Susceptibility of Gastric Mucin

Domperidone-Induced Increase in Lower Oesophageal Sphincter Pressure Does Not Affect Azygos Blood Flow in Patients with Cirrhosis

The Age-, Sex-, and Site-Specific Occurrence of Adenomas and Carcinomas of the Large Intestine within a Defined Population

Mandibular Osteomas in Ulcerative Colitis

Platelet Dysfunction and Alteration of Prostaglandin Metabolism after Chronic Alcohol Consumption

J. Myren, E. Gjone & T. Sørli

H. L. Waldum & P. M. Kleveland 1025

K. Okazaki, M. Miyazaki, S. Onishi & K. Ito 1029

P.-Å. Karlqvist, L. Franzén, R. Sjödahl & C. Tagesson 1039

C. Di Somma, C. Arnulfo, G. Mortola, D. Dato, P. Serafini, R. Rezzo, B. P. Imbimbo & G. Reboa 1046

B. Børkje, S. Ødegaard, D. W. Skagen, K.-J. Andersen & E. Schrumpf 1051

S. U. Friis & E. Gudmand-Høyer 1058

G. Lux, H. Hentschel, H. G. Rohner, H. Brunner, K. Schütze, P. C. Lederer & W. Rösch 1063

P. Cantor, J. J. Holst, S. Knuhtsen & J. F. Rehfeld 1069

B. L. Slomiany, J. Sarosiek, Y. H. Liau, W. Laszewicz & A. Slomiany 1073

A. Braillon, D. Capron-Chivrac, D. Valla, S. S. Lee, J.-P. Capron & D. Lebre 1080

T. J. Eide 1083

J. O. Søndergaard, L. B. Svendsen, J. O. Hegnhøj & I. N. Witt 1089

M. Arai, F. Okuno, S. Nagata, Y. Shigeta, S. Takagi, Y. Ebihara, T. Kobayashi, H. Ishii & M. Tsuchiya 1091

Abstracted in *Excerpta Medica*

Indexed in *Current Contents* and *Index Medicus*

Spanish edition distributed by Sanidad Ediciones, S.A.

Chinese edition distributed by The Shanghai Institute of Digestive Diseases

ISSN 0036-5521

Annual subscription (ten issues per year) NOK 1,300,-/ USD 216.00

Publisher: Norwegian University Press (Universitetsforlaget/AS), P.O. Box 2959 Tøyen, Oslo 6, Norway.
U.S. address: P.O. Box 258, Irvington-on-Hudson, NY 10533, USA